Clinical performance and robustness of blood‐based biomarkers for early detection of amyloid pathology associated with Alzheimer’s disease

Accurate and robust blood‐based biomarkers (BBBMs) of Alzheimer’s disease (AD) are required for identification of symptomatic patients with low likelihood of amyloid pathology before confirmatory diagnostic evaluation. Further evidence on the clinical performance and robustness of BBBMs is required to identify patients for clinical trials and in routine clinical practice. We evaluated the clinical performance and robustness of amyloid‐β 1–42 (Aβ42), amyloid‐β 1–40 (Aβ40), apolipoprotein E4 (ApoE4), phosphorylated‐tau 181 (pTau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NFL) as BBBMs of AD.